How Investors May Respond To Pro Medicus (ASX:PME) Seven-Year A$90m US Cloud Imaging Deal

• In May 2026, Pro Medicus announced it had signed a seven-year, A$90 million contract with Boston-based Beth Israel Lahey Health to roll out its Visage 7 cloud imaging platform across 14 hospitals, with an initial go-live targeted for early 2027.
• An interesting aspect of this deal is its transaction-based licensing model, which ties Pro Medicus’s revenue to Beth Israel Lahey Health’s actual imaging volumes over the contract term.
• We’ll now examine how this large, transaction-based US hospital contract could influence Pro Medicus’s existing investment narrative and growth assumptions.

Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

Pro Medicus Investment Narrative Recap

To own Pro Medicus, you need to believe its cloud based, transaction priced imaging platform can keep winning large U.S. hospital networks and converting backlog into long term, high margin revenue. The Beth Israel Lahey Health contract reinforces that thesis and supports the near term catalyst of continued U.S. deal momentum, but it does not remove the key risk that premium expectations could be challenged if imaging volumes or budgets weaken, or if competitors close the technology gap.

Among recent announcements, the interim FY26 result stands out alongside this contract. For the half year to December 2025, Pro Medicus reported A$128.94 million of revenue and A$171.22 million of net income, highlighting how existing U.S. contracts already translate into strong profitability. The Beth Israel Lahey Health deal slots into that picture by extending the transaction based model across another 14 hospitals, which could matter for how investors think about future revenue mix and earnings resilience.

Yet despite these big contracts, investors should still pay close attention to how a handful of large U.S. clients could...

Read the full narrative on Pro Medicus (it's free!)

Pro Medicus' narrative projects A$462.4 million revenue and A$268.3 million earnings by 2028. This requires 29.5% yearly revenue growth and about A$153.1 million earnings increase from A$115.2 million today.

Uncover how Pro Medicus' forecasts yield a A$326.49 fair value, a 154% upside to its current price.

Exploring Other Perspectives

Before this deal, the most pessimistic analysts still assumed revenue could reach about A$426.1 million and earnings A$235.9 million, yet they highlighted that heavy reliance on long, phased cloud rollouts means any delay or scope change could slow transaction growth. This Beth Israel Lahey Health win might shift those expectations over time, but it is a reminder that your view on timing and execution risk can sit very differently to others.

Explore 15 other fair value estimates on Pro Medicus - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pro Medicus research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Pro Medicus research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pro Medicus' overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 9 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com